Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Carter, L. M.*; Crawford, T. M.*; Sato, Tatsuhiko; Furuta, Takuya; Choi, C.*; Kim, C. H.*; Brown, J. L.*; Bolch, W. E.*; Zanzonico, P. B.*; Lewis, J. S.*
Journal of Nuclear Medicine, 60(12), p.1802 - 1811, 2019/12
Times Cited Count：22 Percentile：80.72(Radiology, Nuclear Medicine & Medical Imaging)Voxel human phantoms have been used for internal dose assessment. More anatomically accurate representation become possible for skins or layer tissues owing to recent developments of advanced polygonal mesh-type phantoms and thus internal dose assessment using those advanced phantoms are desired. However, the Monte Carlo transport calculation by implementing those phantoms require an advanced knowledge for the Monte Carlo transport codes and it is only limited to experts. We therefore developed a tool, PARaDIM, which enables users to conduct internal dose calculation with PHITS easily by themselves. With this tool, a user can select tetrahedral-mesh phantoms, set radionuclides in organs, and execute radiation transport calculation with PHITS. Several test cases of internal dosimetry calculations were presented and usefulness of this tool was demonstrated.
Br-
-methyl-phenylalanine for tumor PET imagingHanaoka, Hirofumi*; Ohshima, Yasuhiro; Suzuki, Yurika*; Yamaguchi, Aiko*; Watanabe, Shigeki; Uehara, Tomoya*; Nagamori, Shushi*; Kanai, Yoshikatsu*; Ishioka, Noriko; Tsushima, Yoshito*; et al.
Journal of Nuclear Medicine, 56(5), p.791 - 797, 2015/05
Times Cited Count：18 Percentile：62.21(Radiology, Nuclear Medicine & Medical Imaging)Br-
-bromobenzylguanidineWatanabe, Shigeki; Hanaoka, Hirofumi*; Liang, J. X.; Iida, Yasuhiko*; Endo, Keigo*; Ishioka, Noriko
Journal of Nuclear Medicine, 51(9), p.1472 - 1479, 2010/09
Times Cited Count：21 Percentile：56.56(Radiology, Nuclear Medicine & Medical Imaging)
Re-MAG3-conjugated bisphosphonate (Re-MAG3-HBP), an agent for treatment of painful bone metastasesOgawa, Kazuma*; Mukai, Takahiro*; Kawai, Keiichi*; Takamura, Norito*; Hanaoka, Hirofumi*; Hashimoto, Kazuyuki; Shiba, Kazuhiro*; Mori, Hirofumi*; Saji, Hideo*
European Journal of Nuclear Medicine and Molecular Imaging, 36(1), p.115 - 121, 2009/01
Times Cited Count：25 Percentile：60.38(Radiology, Nuclear Medicine & Medical Imaging)We have developed a Re-MAG3 complex-conjugated bisphosphonate (Re-MAG3-HBP) for the treatment of painful bone metastases. We assumed competitive inhibitors of protein binding to be useful for procuring a favorable biodistribution of Re-MAG3-HBP because it has been reported that the concurrent administration of 
Tc-MAG3 and drugs with high affinity for serum protein enhanced total clearance and tissue distribution. The protein binding of Re-MAG3-HBP in a human serum albumin solution was significantly decreased by the addition of ceftriaxone. In the biodistribution experiments, pretreatment with ceftriaxone enhanced the clearance of the radioactivity of Re-MAG3-HBP in blood and nontarget tissues but had no effect on accumulation in bone. The findings suggested that the use of protein-binding competitive inhibitors would be effective in improving the pharmacokinetics of radiopharmaceuticals with high affinity for serum protein.
Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal modelOgawa, Kazuma*; Mukai, Takahiro*; Asano, Daigo*; Kawashima, Hidekazu*; Kinuya, Seigo*; Shiba, Kazuhiro*; Hashimoto, Kazuyuki; Mori, Hirofumi*; Saji, Hideo*
Journal of Nuclear Medicine, 48(1), p.122 - 127, 2007/01
We developed a highly stable rhenium-186 (Re)-MAG3 complex-conjugated bisphosphonate, (Re-MAG3-HBP), for the treatment of painful bone metastases. This agent showed a superior biodistribution as a bone-seeking agent in normal mice when compared with Re-HEDP. In this study, we evaluated the therapeutic effects of Re-MAG3-HBP using an animal model of bone metastasis. In the rats treated with Re-HEDP, tumor growth was comparable to that in untreated rats. In contrast, when Re-MAG3-HBP was administered, tumor growth was significantly inhibited. Allodynia induced by bone metastasis was attenuated by treatment with Re-MAG3-HBP or Re-HEDP, but Re-MAG3-HBP tended to be more effective. These results indicate that Re-MAG3-HBP could be useful as a therapeutic agent for the palliation of metastatic bone pain.
Horiuchi, Kazuko*; Konno, Aya*; Ueda, Mayumi*; Fukuda, Yoko*; Nishio, Saori*; Hashimoto, Kazuyuki; Saji, Hideo*
European Journal of Nuclear Medicine and Molecular Imaging, 31(3), p.388 - 398, 2004/03
Times Cited Count：21 Percentile：50.12(Radiology, Nuclear Medicine & Medical Imaging)no abstracts in English
Re-labeled monoclonal antibodyKinuya, Seigo*; Yokoyama, Kunihiko*; Kudo, Miho*; Kasahara, Yoshihito*; Kobayashi, Katsutoshi; Motoishi, Shoji; Onoma, Katsuyuki; Bunko, Hisashi*; Nichigishi, Takatoshi*; Tonami, Norihisa*
Journal of Nuclear Medicine, 42(4), p.596 - 600, 2001/04
no abstracts in English
